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Absence of the spleen and the occurrence of primary
red cell alloimmunization in humans
With its unique anatomy and location amidst the circu-
latory system, the spleen allows an intimate contact
between its resident cells and blood passing through the
organ. Senescent and damaged red cells are primarily
sequestered in the splenic red pulp and consumed by its
macrophages.1 Consequently, this route facilitates the
presentation of non-self antigens of transfused red cells
to splenic immune cells as a first and essential step in red
cell alloimmunization. Indeed, the splenic microenviron-
ment has been demonstrated to play a prominent role in
red cell alloimmunization in mice.2,3 Contrasting these
animal studies, some observational studies in thalassemia
patients suggested splenectomy to be associated with
increased red cell alloimmunization,4,5 while others did
not find any association.6,7
In the study herein, we assessed the association
between the anatomic absence of the spleen and (trans-
fusion-related) red cell alloantibody induction in our mul-
ticenter case-control  Risk Factors for Alloimmunization
to Red Blood Cell Transfusion (R-FACT) study cohort.
This cohort includes 505 alloimmunized cases and 1,010
non-alloimmunized matched controls among a primarily
Caucasian source population of 24,063 patients receiving
their first and subsequent red cell transfusions between
January 2005 and December 2013 at one of six participat-
ing hospitals in the Netherlands, as described earlier.8 A
detailed description of our case-control cohort and the
methodology used has been published recently.9
In summary, cases were identified as all patients who
developed a first transfusion-induced alloantibody during
the course of their transfusion history against the anti-
gens: c, C, e, E, K, Cw, Fya, Fyb, Jka, Jkb, Lea, Leb, Lua, Lub,
M, N, S, or s. Herein, we considered the last (documented
or assumed) antigen mismatched transfusion preceding
the first positive screen (i.e., the Nth transfusion) to likely
have elicited alloimmunization, and defined this as the
‘implicated transfusion’. If this last mismatched transfu-
sion could not be identified due to incomplete donor typ-
ing, the last non-tested unit preceding the first positive
screen was considered as the implicated transfusion.
Based on an ‘incidence density sampling strategy’, for
each identified case we randomly sampled two non-
alloimmunized control subjects out of the source popula-
tion, on the precondition that these controls had received
at least an equivalent number of (lifetime) red cell trans-
fusions in the same study center as the case. The Nth
transfusion in these sampled controls, corresponding to
the implicated transfusion of their matched cases, was
then marked. Subsequently, we constructed a so-called
‘alloimmunization risk period’ in both cases and controls,
stretching from 30 days before to seven days after this
Nth (implicated) transfusion. Finally, we compared the
presence of a history of splenectomy at the time of the
alloimmunization risk period in cases and controls. 
The study protocol was approved by the Ethical
Review Board in Leiden and by the board of each partic-
ipating center. 
At the alloimmunization risk period, splenectomy had
been performed in 20 patients, namely one case (0.2%)
versus 19 controls (1.9%) (Table 1). In 12 patients, splenic
injury was caused by severe trauma or complicated
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Table 1. Demographics and splenectomy details of 19 non-alloimmunized and 1 alloimmunized splenectomized patients. 
Patient Age (years)/ Allo- Indication for splenectomy
sex immunization
A 70/M Yes orthotopic liver transplantation complicated by splenic damage.
B 30/M No total pancreatectomy complicated by retroperitoneal hematoma and splenic infarction.
C 16/F No spontaneous splenic rupture shortly following post allogeneic stem cell transplantation.
D 39/M No severe trauma with intra-abdominal organ damage.
E 34/F No pregnancy complicated by rupture of a splenic artery aneurysm.
F 40/M No severe trauma with intra-abdominal organ damage.
G 74/F No resection of a large intra-abdominal liposarcoma, including splenectomy.
H 58/F No unilateral nephrectomy for renal cell carcinoma complicated by splenic damage.
I 72/F No resection of a large intra-abdominal liposarcoma.
J 55/M No polycythemia vera associated splenomegaly.
K 82/M No distal pancreatectomy with splenectomy.
L 46/M No severe trauma with intra-abdominal organ damage.
M 30/M No severe trauma with intra-abdominal organ damage.
N 63/M No pancreatic necrosis following a history of pancreaticojejunostomy.
O 49/M No severe trauma with intra-abdominal organ damage.
P 76/M No coronary artery bypass surgery complicated by an incarcerated inguinal hernia with secondary
peritonitis and intra-abdominal hemorrhage.
Q 77/F No resection of a large intra-abdominal sarcoma.
R 67/F No adrenalectomy for metastasized adrenal carcinoma complicated by splenic damage.
S 75/M No unilateral nephrectomy for renal cell carcinoma complicated by severe intra-abdominal bleeding.
T 73/M No infective endocarditis with septic embolism and splenic abscesses.
Anti-M and anti-E were detected in patient A on days 23, 23 and 21 after the first allo-M and allo-E exposure, the splenectomy, and the implicated transfusion, respectively.
abdominal surgery, while no patient underwent a
splenectomy in the context of an autoimmune disease.
Sixteen of the splenectomized patients received their
implicated (Nth) transfusion at or after splenectomy
(median 0, range 0-3,612 days). In three other patients,
splenectomy followed the implicated transfusion by 1-4
days. Consequently, in these patients immunization
against the administered blood was considered as being
modulated by the splenectomy. Subsequent red cell
transfusions beyond splenectomy were received by all
but two (patients L and N) controls (median 19 units;
range 0-59, Table 2), with one control being further trans-
fused beyond the study period. Red cell alloantibodies
were not developed (data available up to April 2017).
Only one splenectomized patient developed alloanti-
bodies (patient A). In this patient, anti-E and anti-M were
simultaneously detected 23 days after a combined ortho-
topic liver transplantation and splenectomy. During, and
following on from this surgery, he received 6 E-positive
and at least 8 M-positive units. Using multivariate logistic
regression analysis conditioning on the matched vari-
ables plus identified potential confounders (Online
Supplementary Table S1), we estimated that splenec-
tomized patients had a 20-fold reduced risk of alloimmu-
nization as compared to patients lacking a history of
splenectomy (adjusted relative risk (RR) 0.05, 95% confi-
dence interval (CI) 0.01-0.55). Omitting patients L and N,
who were not further exposed to red cell transfusions fol-
lowing splenectomy, did not change the RR (0.05 [95%CI
0.01-0.62]). 
Since transfusions were administered both before and
after splenectomy, the estimation of an alloimmunization
risk from the time of splenectomy onwards should be
related to both pre- and post-splenectomy red cell expo-
sures. Based on an estimated number of 245 splenec-
tomized patients within the entire source population, we
calculated that 13 splenectomized patients, instead of
only patient A, were expected to have developed alloan-
tibodies had splenectomy not influenced alloimmuniza-
tion (for calculations, see Table 2). We hereby assumed
the red cell exposures of the 19 splenectomized controls
to represent the red cell exposure pattern of all splenec-
haematologica 2017; 102:e290
LETTERS TO THE EDITOR
Table 2. Illustration of expected versus observed numbers of alloimmunized patients within the splenectomized source population. 
Patient T1: number of red cell T2: cumulative number pT1 pT2  P
units received before of red cell units 
splenectomy received up to last
screen
A 0 19 0.000 0.063 0.063
B 0 2 0.000 0.016 0.016
C 15 30 0.061 0.084 0.023
D 0 11 0.000 0.051 0.051
E 0 16 0.000 0.063 0.063
F 0 8 0.000 0.037 0.037
G 0 31 0.000 0.084 0.084
H 0 19 0.000 0.063 0.063
I 4 31 0.027 0.084 0.057
J 0 34 0.000 0.089 0.089
K 0 19 0.000 0.063 0.063
L 2 2 0.016 0.016 0.000
M 0 10 0.000 0.047 0.047
N 21 21 0.067 0.067 0.000
O 0 59 0.000 0.104 0.104
P 30 53 0.084 0.104 0.019
Q 4 13 0.027 0.058 0.031
R 0 21 0.000 0.067 0.067
S 1 38 0.010 0.089 0.079
T 0 53 0.000 0.104 0.104
SUM 1.059
Step 1: Estimation of number of splenectomized patients within the source population. Among 14,901 patients from the Leiden University Medical Center, University
Medical Center Utrecht and Jeroen Bosch Hospital ‘s Hertogenbosch, 155 patient with a documented history of splenectomy receiving red cell transfusions beyond their
splenectomy were identified by searching their clinical files via information technology resources. None of these patients developed red cell antibodies. As these patients
represent 62.0% of the entire source cohort, the total number of splenectomized patients within the source cohort will be approximately 245.  Step 2: Comparison of expect-
ed versus observed number of alloimmunized patients within the splenectomized source population. Based on the cumulative number of red cell units received pre- and
post-splenectomy, and reported cumulative incidences according to number of red cell units transfused,8 the expected alloimmunization risk per splenectomized patient
encountered from splenectomy onwards (Δp) can be deduced from the absolute risk at the time of splenectomy (pT1) and the risk at the time of last serological follow
up (pT2). pT1 = the chance to have developed red cell alloantibodies following the number of red cell exposures at T1. pT2 = the chance to have developed red cell alloan-
tibodies following the number of red cell exposures at T2. Δp= the chance to have developed red cell alloantibodies between T1 and T2 (i.e., following splenectomy). 
P-values were deduced from reported cumulative incidences according to number of red cell units transfused.8 Consequently, had splenectomy not influenced alloimmu-
nization, one would have expected 1.059 alloimmunizations per 20 splenectomized patients. This number corresponds to an estimated total of 13 alloimmunizations
among the estimated 245 splenectomized patients (5.3%). As only one splenectomized patient within the source population developed alloantibodies, it seems conceiv-
able that approximately 12 patients were protected from alloimmunization due to splenectomy, corresponding to a crude relative risk of 0.08.  
tomized patients within the source population. 
To the best of our knowledge, this is the first study in
humans reporting red cell alloimmunization to be highly
unlikely following splenectomy. Our observation under-
lines the spleen’s function in protective adaptive immuni-
ty against non-self antigens present in the circulation,
and corroborates with earlier studies in splenectomized
mice. Even in the setting of poly(I:C) induced inflamma-
tion (a condition strongly linked with alloimmunization),
murine red cell alloimmune responses were completely
abrogated and were suggested to be due to a splenecto-
my induced impairment of CD4+ T-cell priming and
expansion.2,3 Since T-cell priming requires efficient anti-
gen presentation, it seems unsurprising that splenic con-
ventional CD11c+ dendritic cells have been strongly
implicated in murine red cell alloimmunization.10 In
agreement with these findings, the splenic T cell subsets
were shown to be pivotal for antibody production
against both autologous and allogeneic platelet mem-
brane antigens.11 
Contrary to our results, thus far observational studies
in patients with major thalassemia and sickle cell disease
(a population not included in the current study) did not
find any abrogation of red cell antibody development
with splenectomy. Some even concluded that these
patients were more prone to red cell alloimmunization.4,5
Yet, hemoglobinopathy patients in need of splenectomy
are often highly transfusion dependent, causing a prior
high exposure related cumulative alloimmunization risk.8
As such, exposure related confounding cannot be exclud-
ed as most of these studies did not correct for the cumu-
lative exposure at the time of primary alloimmunization.
Second, none reported the timing of alloimmunization to
splenectomy nor the transfusion burden at the time of
splenectomy, leaving the question of whether alloimmu-
nization, or even only CD4+ T-cell sensitization,12 had not
already occurred prior to splenectomy. With regard to the
latter, alloimmunization following splenectomy could as
such represent a T-cell dependent process and may
explain why some hemoglobinopathy patients still devel-
op alloantibodies despite the absence of the spleen. In
addition, it is unknown how a functional deficiency of
the spleen, as is known to be frequent in sickle cell dis-
ease patients, modulates red cell alloimmunization. As
such, we argue that it is important to re-evaluate primary
alloimmunization potentials in hemoglobinopathy
patients with either anatomic or functional asplenia by
carefully taking into account the above mentioned
methodological issues, in order to elucidate the spleen’s
role in immunization against allogeneic blood cells in this
specific patient population. 
Concerning the anti-E and anti-M formed by the
splenectomized patient A, we should first recognize that
they might have developed independently of red cell
exposure, i.e., as so-called “naturally occurring antibod-
ies”. Second, the induction of anti-M (if from the IgM
class) might implicate a T cell-independent humoral
immune response, for which the spleen is known to be
essential.13 Although an accessory spleen, present in over
10% of humans, was not identified via post-splenectomy
CT scanning of the abdomen, some functional splenic tis-
sue might have remained after splenectomy which medi-
ated alloimmunization. Third, the specific combination
of a donor liver transplant with splenectomy could have
caused red cell alloimmunization via pre-primed lympho-
cytes derived from the donor’s liver transplant (i.e., pas-
senger lymphocyte syndrome). A similar mechanism has
been reported in a patient developing nonhemolytic anti-
M after multiorgan transplant.14 Unfortunately, we could
not retrieve the red cell antigenic phenotype of the liver
donor to corroborate this hypothesis. Finally, we do not
imply an absolute abolishment of red cell alloimmuniza-
tion after splenectomy. Indeed, substantial evidence
shows that at least a few asplenic patients are still capa-
ble of constructing a protective immune response follow-
ing an unconjugated polysaccharide vaccination.15 In
addition, the absence of a functional spleen can, at least
partly, be compensated by vaccines targeting a germinal
center B cell response.16 Yet, the non-intravenous route of
vaccines and the common use of conjugates differ consid-
erably from the administration of donor red cells, facili-
tating epitope presentation and efficient induction of 
T cell-dependent alloimmune responses in non-splenic
lymphoid organs. 
In conclusion, our findings suggest that splenectomy is
strongly associated with protection from primary red cell
alloimmunization in the general transfused patient popu-
lation. 
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